Samsung Epis Targets 20 Biosimilars by 2030

SEOUL, Jan. 15 (Korea Bizwire) — Samsung Epis Holdings, the holding company of biosimilar drug maker Samsung Bioepis, said it plans to expand its biosimilar lineup to 20 products by 2030, signaling a more aggressive push to scale its global drug portfolio while branching into novel therapies. Kim Kyung-ah, president and chief executive of Samsung Epis [...]